ArticleDermatology practical & conceptual2023
The Role of Ischemia-modified Albumin and Ischemia-Modified Albumin to Albumin Ratios in Patients with Alopecia Areata.
Article in Dermatology practical & conceptual, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The molecular puzzle of autoinflammatory skin diseases-a review of chosen conditions.Journal of applied genetics · 2025Review
- Recurrent aphthous stomatitis, oxidative stress, and ischemia modified albumin: A cross-sectional study.Medicine · 2025Observational
- Oxidative stress and alopecia areata.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction
objectiveTo investigate the role of ischemia-modified albumin (IMA) and IMA/albumin levels in patients with AA.
methodsThe present prospective crossectional study includes patients ≥18 who were admitted to the Dermatology and Venerology Department of Hitit University Hospital between April 1, 2021, and September 30, 2021. 70 patients participated in the study (n=34 for the study group and n=36 for the control group). Demographic features, clinical characteristics, IMA, and IMA/albumin levels were compared between the groups. The study group was divided into subgroups based on the number of patches, disease duration, and the number of disease attacks. IMA and IMA/albumin levels were compared between each subgroup.
resultsThe study and control groups were similar with regard to demographic features and clinical characteristics. Significant differences were observed between the mean IMA and IMA/albumin ratio (p=0.004 and 0.012, respectively). The study subgroups were comparable in the number of patches, disease duration, and number of disease attacks.
conclusionAlthough oxidative stress is an important component in the etiology of AA, IMA and IMA/albumin may not be useful in the prediction of disease severity in patients with AA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.